Loading
CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes clinical 0.62, literature 0.66, genetic association 0.00, somatic mutation 0.83, animal model 0.39). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Hepatocellular Carcinoma, Sarcoma, NOS, Stomach Adenocarcinoma.
In plain words · CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.
No product in this corpus aims at CACNA1D yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CACNA1D: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 4 nTPM); no normal tissue stained high; highest cancer staining colorectal cancer (6 of 10 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Skin cancer (all types), Gastric & gastro-oesophageal junction cancer, Renal cell carcinoma, Hepatocellular carcinoma, Sarcomas (soft tissue, bone, GIST), Lung cancer (all types) and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q01668; IntOGen CACNA1D; Human Protein Atlas CACNA1D tissue; Open Targets ENSG00000157388 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Williams M.E. et al, Neuron, 1992, "Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype". Source.
Sources: HGNC HGNC:1391 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q01668 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000157388 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.52, gastric cancer 0.53, prostate cancer 0.52, melanoma 0.52, skin cancer 0.57, breast cancer 0.62 (GraphQL API, CC0)); IntOGen CACNA1D (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Location: Membrane (UniProt). Locus 3p21.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues. Blood: lineage enriched (granulocytes 4 nTPM).
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, glioma, head and neck cancer.
HPA CACNA1D tissue · HPA CACNA1D pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CACNA1D" OR ABSTRACT:"CACNA1D" OR TITLE:"calcium voltage-gated channel subunit alpha1 D" OR ABSTRACT:"calcium voltage-gated channel subunit alpha1 D" OR TITLE:"Voltage-dependent L-type calcium channel subunit alpha-1D" OR ABSTRACT:"Voltage-dependent L-type calcium channel subunit alpha-1D" OR TITLE:"Cav1.3" OR ABSTRACT:"Cav1.3" OR TITLE:"CACH3" OR ABSTRACT:"CACH3" OR TITLE:"CACN4" OR ABSTRACT:"CACN4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CACNA1D, not a curated reading list.